Clinical Trials Browser

INDUSTRY × toripalimab × Breast × Clear all

NCT07281976 2026-02-12

A Trial of LBL-024 Monotherapy or Combination Drug in Patients With Triple Negative Breast Cancer

Phase 1/2 Recruiting

Triple Negative Breast Neoplasms

NCT07111832 2025-12-18

A Clinical Trial of SHR-A1811 in the Treatment of Triple-negative Breast Cancer

Phase 3 Recruiting

Triple Negative Breast Neoplasms

NCT06178159 2025-10-01

DV in Combination With Pertuzumab With or Without Toripalimab Neoadjuvant Therapy With HER2-positive Breast Cancer

Phase 2 Recruiting

Breast Neoplasms

NCT07169994 2025-09-12

A Study of YL202 in Combination With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors

Phase 1/2 Recruiting

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT06642545 2025-02-17

Efficacy and Safety Study of Disitamab Vedotin + RC148 vs. Albumin-Paclitaxone ± Toripalimab in HR-/HER2-low Breast Cancer

Phase 2 Recruiting

Breast Neoplasms

NCT06105008 2024-08-23

Study of Disitamab Vedotin With Toripalimab Verus Disitamab Vedotin in Hormone Receptor Positive, HER2-low Locally Advanced or Metastatic Breast Cancer

Phase 2 Withdrawn

Breast Neoplasms

NCT06389006 2024-05-23

To Evaluate the Efficacy and Safety of Disitamab Vedotin Combined With Toripalimab Sequential Chemotherapy as Neoadjuvant Treatment in Patients With HR-positive, HER2-low Breast Cancer

Phase 2 Recruiting

Breast Neoplasms

NCT05955105 2024-05-21

A Study of ILB2109 and Toripalimab in Patients With Advanced Solid Malignancies

Phase 1/2 Recruiting

BreastDermatologicGynecologicHead & NeckSarcomaThoracic

Nasopharyngeal Carcinoma, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Melanoma, Ovarian Neoplasms, Sarcoma, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT05103917 2021-11-02

A Study to Assess the Safety, Tolerability and Antitumor Activity of X4P-001 in Combination With TNBC

Phase 1/2 Unknown

Triple Negative Breast Neoplasms